Infectious Diseases News and Research

RSS

Research gauges reductions in the quality of life during COVID-19

The results of a survey were published on the medRxiv* preprint server, the purpose of which was to assess the relative well-being of the population under Covid-19 restrictions – through 952 survey respondents from France, India, Italy, the UK, and the US.

29 Sep 2021

Columbia University and partners launch and operate New York City's first Pandemic Response Institute

Through a groundbreaking new award from New York City Economic Development Corporation (NYCEDC), Columbia University – through its Mailman School of Public Health – and a consortium of academic, community, government, and corporate partners will launch and operate New York City's first Pandemic Response Institute (PRI).

29 Sep 2021

Universal screening for SARS-CoV-2 among hospitalized patients may be ineffective

Universal screening of all hospital admissions for infection with SARS-CoV-2 is highly inefficient as a screening method in regions with a low prevalence of COVID-19 in the absence of high-risk factors.

29 Sep 2021

Machine learning may predict zoonotic potential of viral genomes

Most emerging infectious diseases of humans (like COVID-19) are zoonotic – caused by viruses originating from other animal species. Identifying high-risk viruses earlier can improve research and surveillance priorities.

28 Sep 2021

NIAID awards approximately $36.3 million to fuel vaccine research for coronaviruses

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded approximately $36.3 million to three academic institutions to conduct research to develop vaccines to protect against multiple types of coronaviruses and viral variants.

28 Sep 2021

Novel polyclonal antibody therapy meets the criteria for graduation to phase 3 in ACTIV-2 trial

The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, which recently expanded its focus to include evaluating outpatient treatment for COVID-19, today announced that SAB-185, a novel polyclonal antibody therapy, has demonstrated safety and efficacy in phase 2 that meet the criteria for graduation to phase 3 in the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial (ACTG A5401).

28 Sep 2021

COVID Moonshot receives key funding to accelerate drug discovery efforts

The COVID Moonshot, a non-profit, open-science consortium of scientists from around the world dedicated to the discovery of globally affordable and easily-manufactured antiviral drugs against COVID-19 and future viral pandemics has received key funding of £8 million from Wellcome, on behalf of the Covid-19 Therapeutics Accelerator.

28 Sep 2021

New 'reporter viruses' make it easier to observe SARS-CoV-2 in real time

A version of SARS-CoV-2, the virus that causes COVID-19 disease, has been successfully modified to glow brightly in cells and animal tissues, providing a real-time way to track the spread and intensity of viral infection as it happens in animal models, researchers at Texas Biomedical Research Institute report in the journal The Proceedings of the National Academy of Sciences.

27 Sep 2021

NYU wins roughly $4 million federal grant to protect transit workers from COVID-19

NYU School of Global Public Health researchers have been awarded a five-year, roughly $4 million grant from the National Institutes of Health to study efforts to protect New York City transit workers from COVID-19 and how these infection prevention and control programs impact the health and well-being of frontline workers.

27 Sep 2021

Characterization of SARS-CoV-2 infections diagnosed after mRNA BNT162b2 vaccination

A team from the National Institute for Infectious Diseases “L. Spallanzani” (INMI) has recently reported their study on 94 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections (47.9% symptomatic, 52.1% asymptomatic) that occurred after the first or second vaccine dose against SARS-CoV-2 in the Lazio region (Central Italy).

27 Sep 2021

SARS-CoV-2 infection less severe in children and youth during first part of the pandemic

New research has found that children and youth may be at low risk of severe acute COVID-19, according to a study conducted during the first half of the pandemic and published in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.210053.

27 Sep 2021

Scientists develop 'elite' antibodies capable of defeating coronavirus variants at extremely low dosage

Japanese scientists created "elite" antibodies that defeat various coronavirus variants even at an extremely low dose through a new method that accelerated the months-long process of finding such extraordinary antibody candidates to just ten days.

27 Sep 2021

Novel antibody candidate shows potent binding to diverse SARS-CoV-2 variant mutations

Twist Bioscience Corporation (Nasdaq: TWST) today reported that its internally-discovered antibody candidate TB202-3 (CoVIC-094), demonstrated potent binding to diverse SARS-CoV-2 variant mutations, including strains with the E484K, N501Y, D614G, Y453F and K417N mutations in pseudovirus assays, indicating this therapeutic antibody may be effective in treating many strains of COVID-19.

25 Sep 2021

Penn scientists win 2021 Lasker Award for the discovery of therapeutic mRNA technology

As mRNA-based SARS-CoV-2 vaccines are deployed to protect hundreds of millions of people across the world and point the way to end the deadly global COVID-19 pandemic, the University of Pennsylvania scientists whose prescient discovery science effort laid the foundation for swift vaccine development have been awarded the 2021 Lasker~DeBakey Clinical Medical Research Award.

24 Sep 2021

Further evidence of safety and efficacy of mRNA-1273 vaccine in preventing symptomatic COVID-19 and SARS-CoV-2 infection

A recent study supports the efficacy of the mRNA-1273 vaccine in preventing COVID-19 illness and disease severity.

24 Sep 2021

A daily pill to treat covid could be just months away, scientists say

Within a day of testing positive for covid-19 in June, Miranda Kelly was sick enough to be scared. At 44, with diabetes and high blood pressure, Kelly, a certified nursing assistant, was having trouble breathing, symptoms serious enough to send her to the emergency room.

24 Sep 2021

Researchers discover how Rift Valley fever virus enters cells

Rift Valley fever virus causes economically devastating outbreaks of hemorrhagic fever in livestock such as sheep, goats and cattle.

24 Sep 2021

Mathematical constructions of SARS-CoV-2 action could help fine-tune prevention and treatment

Mathematical constructions of the action of SARS-CoV-2 and its multiple spikes, which enable its success at infecting cells, can give vaccine developers and pharmaceutical companies alike a more precise picture of what the virus is doing inside us and help fine tune prevention and treatment, mathematical modelers say.

23 Sep 2021

COVID-19 vaccination eases healthcare demand

A new study discusses a model that has been developed to predict the effects of relaxing restrictions on the number of new COVID-19 cases.

23 Sep 2021

Differences in blood gene expression among patients with varying COVID-19 severity

A new study published on the medRxiv* pre-print server and currently undergoing peer-review aims to answer this question through whole blood transcriptomics of individuals with varying degrees of COVID-19 severity. Transcriptomics, done by RNA sequencing, gives insights into the genes expressed in a cell at a given time point. It gives an analysis of all RNA molecules within a cell, in this case, whole blood.

23 Sep 2021

Infectious Diseases News and Research

Research gauges reductions in the quality of life during COVID-19

Columbia University and partners launch and operate New York City's first Pandemic Response Institute

Universal screening for SARS-CoV-2 among hospitalized patients may be ineffective

Machine learning may predict zoonotic potential of viral genomes

NIAID awards approximately $36.3 million to fuel vaccine research for coronaviruses

Novel polyclonal antibody therapy meets the criteria for graduation to phase 3 in ACTIV-2 trial

COVID Moonshot receives key funding to accelerate drug discovery efforts

New 'reporter viruses' make it easier to observe SARS-CoV-2 in real time

NYU wins roughly $4 million federal grant to protect transit workers from COVID-19

Characterization of SARS-CoV-2 infections diagnosed after mRNA BNT162b2 vaccination

SARS-CoV-2 infection less severe in children and youth during first part of the pandemic

Scientists develop 'elite' antibodies capable of defeating coronavirus variants at extremely low dosage

Novel antibody candidate shows potent binding to diverse SARS-CoV-2 variant mutations

Penn scientists win 2021 Lasker Award for the discovery of therapeutic mRNA technology

Further evidence of safety and efficacy of mRNA-1273 vaccine in preventing symptomatic COVID-19 and SARS-CoV-2 infection

A daily pill to treat covid could be just months away, scientists say

Researchers discover how Rift Valley fever virus enters cells

Mathematical constructions of SARS-CoV-2 action could help fine-tune prevention and treatment

COVID-19 vaccination eases healthcare demand

Differences in blood gene expression among patients with varying COVID-19 severity

NGS for Infectious Disease Surveillance eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News